Key result
HDL particle modifications show diagnostic and therapeutic potential across neurodegenerative diseases.
High-density lipoproteins (HDLs) are complex, heterogenous lipoprotein particles, consisting of a large family of apolipoproteins, formed in subspecies of distinct shapes, sizes, and functions and are synthesized in both the brain and the periphery. HDL apolipoproteins are important determinants of Alzheimer's disease (AD) pathology and vascular dementia, having both central and peripheral effects on brain amyloid-beta (Aβ) accumulation and vascular functions, however, the extent to which HDL particles (HLD-P) can exchange their protein and lipid components between the central nervous system (CNS) and the systemic circulation remains unclear. In this review, we delineate how HDL's structure and composition enable exchange between the brain, cerebrospinal fluid (CSF) compartment, and vascular cells that ultimately affect brain amyloid metabolism and atherosclerosis. Accordingly, we then elucidate how modifications of HDL-P have diagnostic and therapeutic potential for brain vascular and neurodegenerative diseases.
No takes yet. Share an insight, caveat, or question.
Valkenburgh et al. (2021) conducted a review in Neurodegenerative diseases, Alzheimer's disease, and vascular dementia. High-density lipoproteins (HDLs) was evaluated. Modifications of high-density lipoprotein particles and their exchange between the brain and systemic circulation offer diagnostic and therapeutic potential for neurodegenerative diseases.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: